AzTrials
AzTrials

Impaired Glucose ToleranceNCT00472342

The Effects of Exercise on Adipokine in Impaired Fasting Glucose or Impaired Glucose Tolerance Patients

A study testing exercise prescription in people with Impaired Glucose Tolerance and Diabetes, run by Yonsei University at 1 site in South Korea.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Many adipokines are thought that related with metabolic disturbance such as glucose intolerance, dyslipidemia, and insulin resistance. It is reported that regular physical training could prevent the progression of diabetes from prediabetes and improve the insulin resistance. Read more about this study

Who is it for?
Ages 30 to 70 years
Conditions the study is for
Impaired Glucose Tolerance, Diabetes
What is being tested?
exercise prescription
How many people
182 participants
Where
1 siteSouth Korea
Study dates
Mar 2007to Dec 2007
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age; 30~70
  • Subjects with IGT and IFG
  • Subjects with having possibility of exercise stress test
  • Subjects with having a strong will to this study

Who cannot join

  • Age <30 or >70
  • Cr more than 1.5 mg/dL
  • AST, ALT levels more than twice as upper normal range
  • Subjects having past history of coronary artery disease

Trial locations and contacts

1 site in 1 country.

Choon Hee Chung, Prefessor contact

82-33-741-0506

cchung@yonsei.ac.kr

South Korea1 site, 1 recruiting
  • Mi Young Lee

    Wŏnju, Gangwon-do, 220-701

    Mi Young Lee, Dr, 82-33-741-0681, domoe46@yonsei.ac.kr

    Recruiting

Other trials in South Korea

About this study

Many adipokines are thought that related with metabolic disturbance such as glucose intolerance, dyslipidemia, and insulin resistance. It is reported that regular physical training could prevent the progression of diabetes from prediabetes and improve the insulin resistance. After physical training, many adipokine levels were changed due to improving insulin resistance.

In this study, we will examine the various adipokine levels such as adiponectin, RBP-4, and adrenomedullin after exercise training through exercise prescription in IFG and IGT patients.

Read the detailed description

Backgrounds: Type 2 diabetes mellitus can be caused by genetic and environmental factors. Type 2 diabetes could be prevented by modifying the environmental risk factors such as physical inactivity, heavy eating, and obesity. It is reported that regular physical training could prevent the progression of diabetes from prediabetes such as impaired glucose tolerance (IGT) and impaired fasting glucose (IFG).

Prediabetes, the term of IGT and IFG, could progress to type 2 diabetes in 30~40 % within 4~5 years. Moreover, cardiovascular and cerebrovascular events are increased in prediabetic patients like as type 2 diabetic patients.

Adipose tissue is thought as a endocrine organ that secrets and regulates various hormones known as adipokines including adiponectin, resistin, leptin, visfatin, tumor necrosis factor (TNF)-α, interleukin-6 (IL-6), and retinol-binding protein 4 (RBP 4). Recently, many adipokines are thought that related with metabolic disturbance such as glucose intolerance, dyslipidemia, and insulin resistance.

Adiponectin is known as anti-diabetic factor exerting actions on muscle fatty acid oxidation and insulin sensitivity. Plasma adiponectin levels are significantly decreased in obese, type 2 diabetes, and insulin resistant patients and correlated with insulin sensitivity. Also, adiponectin has anti-inflammatory and anti-atherogenic effects. So, adiponectin is representative insulin sensitivity marker and may be a protective factor against development of type diabetes. In previous data, there was discrepancy in effects of exercise on adiponectin levels. Some study showed exercise interventions could not have effects on adiponectin levels. However, other study suggested that physical fitness may increase adiponectin levels in obese insulin resistant adults.

RBP-4, secreted by adiocytes, has effects on reducing glucose transporter 4 (GLUT 4) in adipocytes or increasing gluconeogenesis enzyme activity such as PEPCK in the liver. Also, it is known that RBP-4 is elevated in insulin resistant patients such as type 2 diabetes and obesity. After exercise training, RBP-4 levels were decreased in subjects with improvements of insulin resistance.

Adrenomedullin (AM), originally isolated in pheochromocytoma, is recently reported as adipokine. AM is highly expressed in adipocyte of high fat diet mice or obese rat model and elevated in type 2 diabetic patients. Also, AM expression on white and brown adipose tissue was increased after adrenergic stimulation. So, it is expected that AM expression will be changed by exercise.

In this study, we will examine the various adipokine levels such as adiponectin, RBP-4, and adrenomedullin after exercise training through exercise prescription in IFG and IGT patients.

Methods

Subjects Subjects having IFG and IGT on the basis of a 75g oral glucose tolerance test (OGTT) according to American Diabetes Association criteria will be studied.

Inclusion Criteria

  1. Age; 30~70
  2. Subjects with IGT and IFG
  3. Subjects with having possibility of exercise stress test
  4. Subjects with having a strong will to this study

Exclusion Criteria

  1. Age <30 or >70
  2. Cr more than 1.5 mg/dL
  3. AST, ALT levels more than twice as upper normal range
  4. Subjects having past history of coronary artery disease

Study design

  1. Study design - before and after methods
  2. Visit time - baseline, after 3months, after 6months
  3. 1st visit- IGT and IFG diagnosis by 75g OGTT fill up the agreement Lab sampling
  4. 2nd visit - exercise stress test exercise prescription by physician follow wup lab sampling
  5. 3rd visit - follow up lab sampling completing the study
  6. Dietary pattern data - FFQ and 3 day dietary recall Baseline - FFQ and 3 day dietary recall 2nd visit - 3 day dietary recall 3rd visit - 3 day dietary recall After 1 year - FFQ
  7. Exercise pattern data - International Physical Activity Questionnaire (IPAQ)

1st, 2nd, and 3rd visits- IPAQ 8) We will compare the parameters according to results of IPAQ (by tertile) 9) We will adjust the parameters by dietary pattern 10) Anthropometric measurements

  • Height, weight, BMI, waist circumference, hip circumference 11) Exercise capacity - exercise tolerance test and Vmax O2 12) Biochemical markers
  • Glucose, HbA1C, WBC, AST, ALT, GGT, total cholesterol, triglyceride, HDL cholesterol, insulin, C-peptide 13) Adipokine
  • adiponectine, RBP-4, adrenomedullin 14) Insulin resistance marker
  • HOMA-IR 15) Inflammatory marker
  • C-reactive protein (CRP)
Being tested
exercise prescription
Keywords
impaired glucose tolerance, impaired fasting glucose, diabetes, adipokine, adiponectin, RBP-4, adrenomedullin
Medical subject headings
Glucose Intolerance, Diabetes Mellitus

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • exercise prescriptionBehavioural

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Improvements of adipokine levels

    Measured: 6 Months

Secondary outcomes (1)
  1. Prevention of diabetes

    Measured: 1~5 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 May 2007 (estimated)
  2. Study startMar 2007
  3. Study completionDec 2007 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
182 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00472342
Sponsor's protocol ID
kenshin46
Status last verified
May 2007
First submitted
10 May 2007
Last updated
11 May 2007
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A study testing exercise prescription in people with Impaired Glucose Tolerance and Diabetes, run by Yonsei University at 1 site in South Korea.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 11 May 2007. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Choon Hee Chung, Prefessor (82-33-741-0506, cchung@yonsei.ac.kr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Improvements of adipokine levels (time frame: 6 Months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 May 2007.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in